Studying Genes Using Cord Blood and Placenta Samples From Relatively Healthy Newborns and Samples From Younger Patients With Wilms Tumor

NCT01576211 — Completed, 40 participants, Children's Oncology Group
ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Investigating the Frequency of Loss of Imprinting Across a Birth Cohort and the Link DNA Methylation Plays

RegistryNCT01576211
StatusCompleted
Study typeObservational
Enrollment40 (Estimated)
SponsorChildren's Oncology Group (Network); collaborators: National Cancer Institute (NCI)
ConditionsKidney Cancer
InterventionsDNA methylation analysis, RNA analysis, allele-specific oligonucleotide real-time quantitative polymerase chain reaction, gene expression analysis, nucleic acid sequencing, polymorphism analysis, laboratory biomarker analysis (Genetic, other)
Datesstart 2012-04-01, primary completion 2016-05-01, first posted 2012-04-12, last updated 2016-05-18

Related Papers Related Patents Related Grants Related Experts
All trials for Kidney Cancer All trials of DNA methylation analysis All trials of RNA analysis

-Summary

RATIONALE: Studying samples of blood and tissue from newborns and from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research trial studies cord blood and placenta tissue from newborns, and tumor tissue samples from patients with Wilms tumor.

Expand all sections  ·  Collapse all

+Detailed description

OBJECTIVES:

* What is the frequency of loss of imprinting at birth (in the cord blood and placenta) in a relatively healthy birth cohort?
* Does deoxyribonucleic acid (DNA) methylation levels at imprinting genes have a direct association to the gene expression?

OUTLINE: Archived tumor tissue, cord blood, and placenta samples are analyzed for DNA methylation, single nucleotide polymorphism, and gene expression by polymerase chain reaction (PCR), pyrosequencing, and quantitative real-time PCR. Information regarding gender and age of the samples are also collected, if possible.

+Arms and interventions

  • DNA methylation analysis (Genetic)
  • RNA analysis (Genetic)
  • allele-specific oligonucleotide real-time quantitative polymerase chain reaction (Genetic)
  • gene expression analysis (Genetic)
  • nucleic acid sequencing (Genetic)
  • polymorphism analysis (Genetic)
  • laboratory biomarker analysis (Other)

+Outcome measures

Primary outcomes

  • Frequency of loss of imprinting at birth
  • Association between methylation levels and gene expression

+Eligibility

Sex: All, ages: any to 21 Years, accepts healthy volunteers

DISEASE CHARACTERISTICS:

* Wilms tumor tissue samples from Caucasians (fresh or frozen), or DNA and ribonucleic acid (RNA) samples already isolated from patients registered on Children's Oncology Group Wilms tumor protocols
* Normal/control blood samples from matched individuals
* Cord blood/ placenta samples from the Michels lab Epigenetic Birth Cohort

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* Not specified

+Investigators